The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
Condition: Prostate Cancer, Cardiovascular Disease
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT03127631
Sponsor: McMaster University
Eligibility:
- Age: minimum 45 Years maximum N/A
- Gender: Male
Inclusion Criteria:
- 1. A man with a diagnosis of prostate cancer that is either:
- new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
- treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
- to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit
Exclusion Criteria:
- Patients will be excluded if they fulfill any of the following:
- are unwilling to provide consent or
- are <45 years of age, or
- prostate cancer was found incidentally following cystectomy for bladder cancer
- Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
- see a cardiologist every year, or
- both take a statin and have systolic blood pressure ≤130mmHg
View trial on ClinicalTrials.gov